VITRUVIAE Presents New Solid Tumor Data For Lead T Cell Engager at ASCO 2025

VITRUVIAE is proud to present compelling in vivo preclinical results demonstrating the efficacy of our innovative therapies for the treatment of leukemias and solid tumors. These findings highlight the potential of our novel immunotherapy platform to address critical unmet needs in oncology.

Explore the detailed data and abstract at the ASCO Annual Meeting:
ASCO Abstract #246805